Clinical trial NCT05785754: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Official title: A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Advanced or Metastatic Solid Tumors
Lead sponsor: DynamiCure Biotechnology
Sponsor class: INDUSTRY
First posted: 2023-03-27
Enrollment: 257
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11, an anti-CD93 monoclonal antibody, as a monotherapy and in combination in patients with advanced or metastatic solid tumors.

Detailed description: The drug being tested in this study is called DCSZ11. DCSZ11 is being tested to treat people who have advanced or metastatic solid tumors. The study will include a dose escalation phase and a dose expansion phase.

The study will enroll approximately 138 patients in dose escalation, and approximately 113 participants in the dose expansion phase. Participants will receive escalating doses of DCSZ11 and a fixed dose of pembrolizumab until DCSZ11 doses for phase 1b are selected:

* Phase 1a DCSZ11 monotherapy Dose Escalation.
* Phase 1a DCSZ11 in combination with fixed dose of pembrolizumab Dose Escalation.

Once Phase 1b doses are selected for Phase 1b, participants of select advanced or metastatic solid tumors will receive DCSZ11 in below defined cohorts in Phase 1b:

* Phase 1b cohort 1 NSCLC.
* Phase 1b cohort 2 Microsatellite Stable Colorectal Cancer (MSS-CRC) without liver involvement.
* Phase 1b cohort 3 MSS-CRC with liver involvement.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is 60 months. Participants will make multiple visits to the clinic, and survival follow-up for a maximum of up to 12 months after the last dose of the study drug.

Eligibility criteria: Selected Inclusion Criteria:

1. Male or female patients ≥ 18 years of age.
2. Have a histologically or cytologically documented, advanced (metastatic and/or unresectable) solid tumor that has progressed on or after standard therapy (relapsed/refractory patients; patients must have failed at least one prior line of therapy) or for whom there is no effective standard therapy based on the Investigator's judgment.
3. At least 1 measurable lesion according to RECIST Version 1.1.
4. Patients must have a lesion that can be biopsied with acceptable clinical risk and agree to have a biopsy at Screening and on treatment.
5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
6. Adequate organ function and bone marrow reserve as indicated by the following laboratory assessments performed within 14 days prior to the first dose of study drug.
7. For female patients of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test and agree to use highly effective contraception.
8. For men who are not surgically sterile must agree to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating sperm.
9. The patient is capable of understanding and complying with the protocol and has signed the required ICF. The appropriate ICF must be signed before relevant study procedures are performed. If applicable, the female partner of a male patient understands and signs the pregnant partner's ICF.

Selected Exclusion Criteria:

1. Received systemic anticancer treatments or investigational products within 14 days before the first dose of the study drug or 5 half-lives, whichever is shorter.
2. Received extended field radiotherapy ≤4 weeks before the start of treatment (≤7 days for limited field radiation for palliation outside the chest or brain).
3. Patients with second malignancy within the previous 3 years, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, cervical carcinoma in situ, resected colorectal adenomatous polyps, breast cancer in situ, or other malignancy for which the patient is not on active anticancer therapy.
4. Systemic arterial thrombotic or embolic events, such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 3 months prior to the first dose of study drug.
5. Systemic venous thrombotic events (eg, deep vein thrombosis) or pulmonary arterial events (eg, pulmonary embolism) within 1 month prior to the first dose of study drug. Patients with venous thrombotic events prior to the first dose of study drug on stable anticoagulation therapy are eligible.
6. Left ventricular ejection fraction (LVEF) \< 50%
7. Major surgery within 4 weeks and minor surgery within 2 weeks of the first dose of study drug; following surgeries, all surgical wounds must be healed and free of infection or dehiscence.
8. Marked proteinuria ≥ 2 g/24 hours and/or nephrotic syndrome. Patients with proteinuria 2+ or greater urine dipstick reading should undergo further assessment, eg, a 24-hour urine collection.
9. For patients receiving a combination with pembrolizumab:

   1. History of adverse events related to immunotherapy that required treatment discontinuation.
   2. History of autoimmune disease requiring systemic immunosuppressive therapy with daily doses of prednisone \>10 mg/day or equivalent doses, or any other form of immunosuppressive therapy. Hormone therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered an excluded form of systemic treatment of an autoimmune disease.
   3. History of noninfectious pneumonitis that required steroids or a history of interstitial lung disease.
   4. Evidence of active, noninfectious pneumonitis.
   5. History of allogeneic tissue or solid organ transplant.
10. History of any of the following ≤6 months before first dose: congestive heart failure New York Heart Association Grade III or IV, unstable angina, myocardial infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension despite appropriate medical therapy, ongoing symptomatic cardiac arrhythmias \>Grade 2, or any other serious cardiac condition (e.g., pericardial effusion or restrictive cardiomyopathy). Chronic atrial fibrillation on stable anticoagulant therapy is allowed.
11. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs or has compromised ability to provide written informed consent.
12. Female patients who are pregnant or lactating and breastfeeding.

Primary outcomes:
measure: Phase 1a: Incidence of dose limiting toxicites (DLTs)
timeFrame: 21 days
measure: Phase 1a: Frequency and severity of treatment emergent adverse events
timeFrame: up to 3 years
measure: Phase 1b: Overall response rate (ORR) per Investigator-assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST)
timeFrame: 1 year
Secondary outcomes:
measure: Phase 1a: Overall response rate (ORR) per Investigator-assessed RECIST v1.1
timeFrame: 1 year
measure: Phase 1a and b: Overall response rate (ORR) per Investigator-assessed consensus guideline developed by the RECIST Working Group for the use of modified RECIST, Version 1.1 in cancer immunotherapy trials (iRECIST)
timeFrame: 1 year
measure: Phase 1a and b: Duration of response (DOR) as determined per Investigator assessment by RECIST v1.1 and iRECIST
timeFrame: 1 year
measure: Phase 1 a and b: Disease control rate (DCR) as determined per Investigator assessment by RECIST v1.1 and iRECIST.
timeFrame: 1 year
measure: Phase 1a and b: Progression free survival (PFS) as determined per Investigator assessment by RECIST v1.1 and iRECIST.
timeFrame: 3 years
measure: Phase 1 a and b: Overall survival (OS)
timeFrame: 3 years
measure: Phase 1 and b: Pharmacokinetic parameters of DCSZ11
timeFrame: 2 years
measure: Phase 1 a and b: Incidence of anti-drug antibody (ADA) and neutralizing antibodies (NAbs) against DCSZ11
timeFrame: 2 years
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama
state: Alabama
city: Phoenix
country: United States
facility: Mayo Clinic
state: Arizona
city: Scottsdale
country: United States
facility: HonorHealth
state: Arizona
city: Aurora
country: United States
facility: University of Colorado
state: Colorado
city: Denver
country: United States
facility: Sarah Cannon Research Institute Denver Healthone
state: Colorado
city: New Haven
country: United States
facility: Yale Cancer Center
state: Connecticut
city: Jacksonville
country: United States
facility: Mayo Clinic
state: Florida
city: Miami
country: United States
facility: University of Miami
state: Florida
city: Baltimore
country: United States
facility: John Hopkins Sidney Kimmel Comprehensive Cancer Center
state: Maryland
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Bronx
country: United States
facility: MonteFiore
state: New York
city: Columbus
country: United States
facility: Ohio State University
state: Ohio
city: Nashville
country: United States
facility: SCRI Oncology Partners
state: Tennessee
city: Randwick
country: Australia
facility: Scientia Clinical Research
state: New South Wales
city: Sydney
country: Australia
facility: St Vincent's Hospital
state: New South Wales
city: Bedford Park
country: Australia
facility: Southern Oncology Clinical Research Unit (SOCRU)
state: South Australia
city: Woodville South
country: Australia
facility: The Queen Elizabeth Hospital (TQEH)
state: South Australia
city: Clayton
country: Australia
facility: Monash Health
state: Victoria
city: Malvern
country: Australia
facility: Cabrini Hospital
state: Victoria
city: Nedlands
country: Australia
facility: Linear Clinical Research Limited
state: Western Australia
city: Douglas
country: Australia
facility: Townsville Hospital
city: Liverpool
country: Australia
facility: Liverpool Hospital
city: South Brisbane
country: Australia
facility: Mater Misericordiae Health Services Brisbane Ltd
city: Wahroonga
country: Australia
facility: Sydney Adventist Hospital
city: Busan
country: Korea, Republic of
facility: Inje University Haeundae Paik Hospital
city: Busan
country: Korea, Republic of
facility: Dong-a University Hospital
city: Gyeonggi-do
country: Korea, Republic of
facility: Cha University Bundang Medical Center
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Chung-ho Memorial Hospital
city: Tainan
country: Taiwan
facility: National Cheng Kung University Hospital
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
References: